AI Article Synopsis
- Advances in genetic testing are enhancing the understanding of pediatric cardiomyopathies, leading to new targeted therapies rather than traditional treatments focused on chronic heart failure.
- A comprehensive review of literature from 2000 to 2022 highlights specific therapies for various genetically distinct pediatric heart failure conditions, including hypertrophic cardiomyopathy and Duchenne muscular dystrophy.
- The findings suggest a promising future for pediatric heart failure treatment by concentrating on molecular causes rather than just addressing symptoms, potentially improving patient outcomes significantly.
Article Abstract
Background And Objective: Improvement in the affordability and convenience of genetic testing has rapidly expanded the understanding of the mechanistic causes of various pediatric cardiomyopathies. Concurrently, new therapies are being developed to better-target specific pathologies as opposed to classic therapies that treat the maladaptive processes of chronic heart failure. This review will discuss the advances in genetic testing and specific therapies that have been shown to benefit or potentially benefit genetically distinct subsets of the pediatric population with heart failure or at risk of developing heart failure.
Methods: We undertook a comprehensive database search (January 2000-August 2022) of PubMed, utilizing terms 'pediatric', 'cardiomyopathy', 'heart failure', 'genetics', and 'precision medicine'. Additional notable studies were obtained from ClinicalTrials.gov. Studies published in English that examine genetic basis and treatment modalities of pediatric heart failure.
Key Content And Findings: New and investigational therapies for hypertrophic cardiomyopathies associated with obstruction or Noonan syndrome, Fabry cardiomyopathy, Barth syndrome, Duchenne muscular dystrophy, single ventricle failure, and heart failure in specific demographics are discussed.
Conclusions: The rapid expansion of the genetic understanding of cardiomyopathy and heart failure as well as tailored therapies to specific molecular causes holds great promise for the future of pediatric heart failure treatment. Whereas conventional heart failure therapies target the maladaptive remodeling response that leads to worsening of heart failure, these therapies target the molecular causes of cardiomyopathy and heart failure in certain populations allowing for a potential to more significantly impact the clinical trajectory of pediatric heart failure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080489 | PMC |
| http://dx.doi.org/10.21037/tp-22-431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Body Mass Index and Clinical Outcomes in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Acta Cardiol Sin
January 2025
School of Medicine, National Yang Ming Chiao Tung University.
Article Synopsis
- The study investigates the "obesity paradox," focusing on overweight and obese patients who underwent percutaneous coronary intervention (PCI) for coronary artery disease.
- Over a follow-up period averaging about 65 months, results showed that 17.4% of patients experienced adverse cardiovascular events, with a notable J-shaped relationship indicating that those classified as overweight (BMI 25.0-29.9 kg/m) had lower risks of total and major cardiovascular events.
- The findings suggest that overweight individuals may have better cardiovascular outcomes post-PCI compared to those with a normal BMI.
2025 Update Consensus of Tc-Pyrophosphate Scintigraphy in the Transthyretin Cardiac Amyloidosis from the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.
Acta Cardiol Sin
January 2025
Division of Cardiology, Cardiovascular Medical Center, and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City.
This 2025 updated consensus outlines the diagnostic strategy for transthyretin amyloid cardiomyopathy (ATTR-CM). Given that ATTR-CM is a significant contributor to heart failure, this article emphasizes the importance of making an early and precise diagnosis, particularly as new therapeutic options become available. Highlighting the critical importance of an early and accurate diagnosis, particularly in light of emerging therapeutic modalities, this consensus underscores the central role of Tc-pyrophosphate (PYP) scintigraphy as a non-invasive diagnostic tool.
View Article and Find Full Text PDFPrevalence and predictors of poor heart failure treatment outcomes in Ethiopia: a systematic review and meta-analysis.
Front Cardiovasc Med
December 2024
Department of Pharmacy, Institute of Health Science, Wallaga University, Nekemte, Ethiopia.
Background: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Various factors can exacerbate disease progression in patients with HF and negatively impact treatment outcomes. This study aims to evaluate the pooled prevalence and contributing factors associated with poor heart failure treatment outcomes in Ethiopia.
View Article and Find Full Text PDFDouble Outlet Right Ventricle: A Rare Finding in a 15-Month-Old Female With Failure to Thrive.
Clin Case Rep
January 2025
Department of Radiology and Radiotherapy, School of Medicine, College of Health Sciences Makerere University Kampala Uganda.
Double outlet right ventricle (DORV) is a rare congenital heart defect where both the aorta and pulmonary artery originate from the right ventricle, often accompanied by additional cardiac anomalies to mitigate circulatory imbalance, though such compensations usually fail. We report a 15-month-old infant with recurrent respiratory infections and poor weight gain, referred for computed tomography angiography. Physical examination showed a small, non-syndromic infant with pallor, tachypnea, irritability, and finger clubbing.
View Article and Find Full Text PDFTranscatheter Caval Implantation for Severe Tricuspid Regurgitation.
Curr Cardiol Rep
January 2025
Department of Cardiovascular Medicine, Heart Vascular & Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, OH, 44195, USA.
Purpose Of Review: We describe the evolution of caval valve implantation (CAVI) as a treatment for severe symptomatic tricuspid regurgitation (TR) in the high surgical risk patient.
Recent Findings: Surgical treatment of severe TR is often limited by the high surgical risk of the patients who tend to develop severe secondary TR. Coaptation, annuloplasty, and orthotopic replacement strategies are all limited by annular and leaflet geometry, prior valve repair, and the presence of cardiac implantable device leads.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!